Trial Profile

A Multicentre, Open-label, Phase I/II Study Investigating the Safety, Tolerability, and Preliminary Efficacy of 225Ac-SSO110 in Participants With Extensive Stage Small Cell Lung Cancer (ES-SCLC) or Merkel Cell Carcinoma (MCC) Receiving Standard of Care (SoC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Actinium-225-satoreotide-Ariceum-Therapeutics (Primary) ; Atezolizumab; Avelumab; Durvalumab; Pembrolizumab; Retifanlimab
Indications Merkel cell carcinoma; Small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms SANTANA-225
Sponsors Ariceum Therapeutics

11 Nov 2025 According to an Ariceum Therapeutics media release, first patient has been dosed in this study. Initial safety data expected in 2026.
09 Oct 2025 According to an Ariceum Therapeutics media release, the initial safety data from SANTANA-225 expected in 2026 and preliminary efficacy data in 2027.
09 Oct 2025 Results presented in the Ariceum Therapeutics media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com